[6-K] Safe Bulkers, Inc. Current Report (Foreign Issuer)
Alvotech鈥檚 July 2025 Form 6-K details governance, commercial, regulatory and financing actions since its Q1 report.
- Governance: Six directors re-elected; veteran executive Linda J贸nsd贸ttir appointed CFO; COO Faysal Kalmoua exits board and management.
- Commercial: Advanz Pharma partnership broadened to three new biosimilars (milestones up to 鈧�160 m) and separate AVT10 (Cimzia) deal; global Keytruda biosimilar co-development with Dr. Reddy鈥檚.
- M&A: Acquired Swiss packager Ivers-Lee and Xbrane鈥檚 Swedish R&D team plus Cimzia candidate for c.SEK 275 m.
- Pipeline: CHMP positive opinion for AVT06 (Eylea); AVT23 (Xolair) study shows therapeutic equivalence.
- Manufacturing risk: FDA pre-approval inspection (26 Jun鈥�4 Jul) issued Form 483 citing operational, documentation and quality control deficiencies; detailed response submitted 25 Jul.
- Financing: Oversubscribed SDR IPO (SEK 39 m) and institutional placement (SEK 750 m) add >3,000 new holders; term-loan amendment folds second tranche, trims margin to SOFR+6.0%, facility now $1.081 bn, cash $152 m.
New capital and partnerships enhance growth prospects, but regulatory remediation is critical for near-term BLA approvals.
Il Form 6-K di Alvotech di luglio 2025 riporta le azioni di governance, commerciali, regolatorie e finanziarie intraprese dalla pubblicazione del rapporto del primo trimestre.
- Governance: Sei amministratori rieletti; la veterana Linda J贸nsd贸ttir nominata CFO; il COO Faysal Kalmoua lascia il consiglio e la direzione.
- Commerciale: Partnership con Advanz Pharma estesa a tre nuovi biosimilari (milestone fino a 160 milioni di euro) e accordo separato per AVT10 (Cimzia); co-sviluppo globale del biosimilare di Keytruda con Dr. Reddy鈥檚.
- M&A: Acquisizione del confezionatore svizzero Ivers-Lee e del team R&D svedese di Xbrane, oltre al candidato Cimzia per 275 milioni di corone svedesi.
- Pipeline: Opinione positiva CHMP per AVT06 (Eylea); studio su AVT23 (Xolair) dimostra equivalenza terapeutica.
- Rischio produttivo: Ispezione FDA pre-approvazione (26 giugno鈥�4 luglio) ha emesso il Form 483 evidenziando carenze operative, documentali e di controllo qualit脿; risposta dettagliata inviata il 25 luglio.
- Finanziamenti: IPO SDR sovrasottoscritta (39 milioni SEK) e collocamento istituzionale (750 milioni SEK) hanno aggiunto oltre 3.000 nuovi azionisti; modifica del prestito a termine che elimina la seconda tranche, riduce il margine a SOFR+6,0%, struttura ora a 1,081 miliardi di dollari, liquidit脿 di 152 milioni di dollari.
Il nuovo capitale e le partnership rafforzano le prospettive di crescita, ma la risoluzione delle questioni regolatorie 猫 fondamentale per le approvazioni BLA a breve termine.
El Formulario 6-K de Alvotech de julio de 2025 detalla las acciones de gobernanza, comerciales, regulatorias y financieras desde su informe del primer trimestre.
- Gobernanza: Seis directores reelegidos; la ejecutiva veterana Linda J贸nsd贸ttir nombrada CFO; el COO Faysal Kalmoua sale del consejo y la gesti贸n.
- Comercial: Ampliaci贸n de la colaboraci贸n con Advanz Pharma a tres nuevos biosimilares (hitos hasta 鈧�160 millones) y acuerdo separado para AVT10 (Cimzia); co-desarrollo global del biosimilar de Keytruda con Dr. Reddy鈥檚.
- Fusiones y Adquisiciones: Adquisici贸n del envasador suizo Ivers-Lee y del equipo de I+D sueco de Xbrane, adem谩s del candidato Cimzia por 275 millones de coronas suecas.
- Pipeline: Opini贸n positiva del CHMP para AVT06 (Eylea); estudio de AVT23 (Xolair) demuestra equivalencia terap茅utica.
- Riesgo de fabricaci贸n: Inspecci贸n pre-aprobaci贸n de la FDA (26 jun鈥�4 jul) emiti贸 el Formulario 483 se帽alando deficiencias operativas, documentales y de control de calidad; respuesta detallada enviada el 25 de julio.
- Financiamiento: IPO SDR sobresuscrita (39 millones SEK) y colocaci贸n institucional (750 millones SEK) suman m谩s de 3,000 nuevos accionistas; enmienda del pr茅stamo a plazo que elimina la segunda tranche, reduce el margen a SOFR+6.0%, facilidades ahora en $1.081 mil millones, efectivo $152 millones.
El nuevo capital y las alianzas mejoran las perspectivas de crecimiento, pero la remediaci贸n regulatoria es cr铆tica para las aprobaciones BLA a corto plazo.
Alvotech鞚� 2025雲� 7鞗� Form 6-K電� 1攵勱赴 氤搓碃靹� 鞚错泟鞚� 瓯半矂雱岇姢, 靸侅梾, 攴滌牅 氚� 鞛 頇滊彊鞚� 靸侅劯頌� 靹る獏頃╇媹雼�.
- 瓯半矂雱岇姢: 6氇呾潣 鞚挫偓 鞛劆鞛�; 氩犿厡霝� 鞛勳洂 Linda J贸nsd贸ttir臧� CFO搿� 鞛勲獏; COO Faysal Kalmoua電� 鞚挫偓須� 氚� 瓴届榿歆勳棎靹� 韲挫瀯.
- 靸侅梾: Advanz Pharma鞕�鞚� 韺岉姼雱堨嫮鞚� 3臧滌潣 鞁犼窚 氚旍澊鞓れ嫓氚�霟 頇曤寑(毵堨澕鞀ろ啢 斓滊寑 鈧�1鞏� 6觳滊); 氤勲弰 AVT10(Cimzia) 瓿勳暯 觳搓舶; Dr. Reddy鈥檚鞕� 鞝� 靹戈硠 Keytruda 氚旍澊鞓れ嫓氚�霟� 瓿惦彊 臧滊皽.
- M&A: 鞀れ渼鞀� 韽灔鞐呾泊 Ivers-Lee 氚� Xbrane鞚� 鞀れ洦雿� 鞐瓣惮臧滊皽韺�瓿� Cimzia 頉勲炒 氍检鞚� 齑� 2鞏� 7,500毵� SEK鞐� 鞚胳垬.
- 韺岇澊顶勲澕鞚�: AVT06(Eylea)鞐� 雽�頃� CHMP 旮嶌爼鞝� 鞚橁铂; AVT23(Xolair) 鞐瓣惮鞐愳劀 旃橂鞝� 霃欕摫靹� 鞛呾.
- 鞝滌“ 毽姢韥�: FDA 靷爠 鞀轨澑 瓴�靷�(6鞗� 26鞚紐7鞗� 4鞚�)鞐愳劀 鞖挫榿, 氍胳劀頇� 氚� 頀堨 甏�毽� 瓴绊暔鞚� 歆�鞝來晿電� Form 483 氚滍枆; 7鞗� 25鞚� 靸侅劯 雼惦硛 鞝滌稖.
- 鞛: 齑堦臣 觳暯霅� SDR IPO(3,900毵� SEK) 氚� 旮瓣磤 氚办爼(7鞏� 5,000毵� SEK)鞙茧 3,000氇� 鞚挫儊鞚� 鞁犼窚 欤检＜ 頇曤炒; 臁瓣贝攵� 雽�於� 靾橃爼鞙茧 霊� 氩堨Ц 韸鸽灉旃� 韽愳, 毵堨 SOFR+6.0%搿� 臁办爼, 鞁滌劋 頃滊弰電� 10鞏� 8,100毵� 雼煬, 順勱笀鞚� 1鞏� 5,200毵� 雼煬.
靸堧鞖� 鞛愲掣瓿� 韺岉姼雱堨嫮鞚� 靹膘灔 鞝勲鞚� 臧曧檾頃橃毵�, 雼赴 BLA 鞀轨澑鞐愲姅 攴滌牅 氍胳牅 頃搓舶鞚� 頃勳垬鞝侅瀰雼堧嫟.
Le Formulaire 6-K d'Alvotech de juillet 2025 d茅taille les actions de gouvernance, commerciales, r茅glementaires et financi猫res depuis son rapport du premier trimestre.
- Gouvernance : Six administrateurs r茅茅lus ; la cadre exp茅riment茅e Linda J贸nsd贸ttir nomm茅e CFO ; le COO Faysal Kalmoua quitte le conseil et la direction.
- Commercial : Partenariat avec Advanz Pharma 茅tendu 脿 trois nouveaux biosimilaires (jalons jusqu'脿 160 M鈧�) et accord s茅par茅 pour AVT10 (Cimzia) ; co-d茅veloppement mondial du biosimilaire de Keytruda avec Dr. Reddy鈥檚.
- Fusions & Acquisitions : Acquisition de l鈥檈mballeur suisse Ivers-Lee et de l鈥櫭﹒uipe R&D su茅doise de Xbrane, ainsi que du candidat Cimzia pour 275 MSEK.
- Pipeline : Avis positif du CHMP pour AVT06 (Eylea) ; 茅tude AVT23 (Xolair) d茅montrant une 茅quivalence th茅rapeutique.
- Risque de fabrication : Inspection pr茅-approbation FDA (26 juin鈥�4 juillet) ayant 茅mis un Form 483 signalant des d茅ficiences op茅rationnelles, documentaires et de contr么le qualit茅 ; r茅ponse d茅taill茅e soumise le 25 juillet.
- Financement : IPO SDR sursouscrite (39 MSEK) et placement institutionnel (750 MSEK) ajoutant plus de 3 000 nouveaux actionnaires ; modification du pr锚t 脿 terme supprimant la deuxi猫me tranche, r茅duisant la marge 脿 SOFR+6,0 %, facilit茅 port茅e 脿 1,081 Md$ et tr茅sorerie de 152 M$.
Les nouveaux capitaux et partenariats renforcent les perspectives de croissance, mais la correction r茅glementaire est cruciale pour les approbations BLA 脿 court terme.
Der Form 6-K von Alvotech im Juli 2025 beschreibt Governance-, kommerzielle, regulatorische und finanzielle Ma脽nahmen seit dem Q1-Bericht.
- Governance: Sechs Direktoren wiedergew盲hlt; erfahrene Managerin Linda J贸nsd贸ttir zur CFO ernannt; COO Faysal Kalmoua verl盲sst Vorstand und Management.
- Kommerziell: Partnerschaft mit Advanz Pharma auf drei neue Biosimilars ausgeweitet (Meilensteine bis zu 160 Mio. 鈧�) und separater AVT10 (Cimzia) Vertrag; globale Co-Entwicklung des Keytruda-Biosimilars mit Dr. Reddy鈥檚.
- M&A: Erwerb des Schweizer Verpackers Ivers-Lee sowie des schwedischen F&E-Teams von Xbrane plus Cimzia-Kandidaten f眉r 275 Mio. SEK.
- Pipeline: Positives CHMP-Gutachten f眉r AVT06 (Eylea); Studie zu AVT23 (Xolair) zeigt therapeutische 脛quivalenz.
- Herstellungsrisiko: FDA-Vorabinspektion (26. Juni鈥�4. Juli) stellte im Form 483 betriebliche, dokumentarische und Qualit盲tskontrollm盲ngel fest; detaillierte Antwort am 25. Juli eingereicht.
- Finanzierung: 脺berzeichnetes SDR-IPO (39 Mio. SEK) und institutionelle Platzierung (750 Mio. SEK) bringen >3.000 neue Aktion盲re; 脛nderung des Terminkredits hebt zweite Tranche auf, senkt Marge auf SOFR+6,0 %, Kreditrahmen nun 1,081 Mrd. USD, Cash 152 Mio. USD.
Neues Kapital und Partnerschaften st盲rken die Wachstumsaussichten, doch regulatorische Nachbesserungen sind f眉r kurzfristige BLA-Zulassungen entscheidend.
- 鈧�160 m milestone expansion of Advanz Pharma partnership covering three new biosimilars
- Global Keytruda biosimilar collaboration with Dr. Reddy鈥檚 broadens high-value oncology pipeline
- CHMP positive opinion for AVT06 and successful AVT23 efficacy study de-risk European approvals
- SEK 789 m equity raises were oversubscribed, adding >3,000 shareholders and improving liquidity
- Term-loan amendment lowers interest by 50 bp and simplifies capital structure, reducing financing costs
- FDA Form 483 cites multiple manufacturing and documentation deficiencies that could delay four pending BLAs
- Executive turnover with COO departure may disrupt operational continuity during critical remediation phase
Insights
TL;DR 鈥� Strong deals and financing offset by FDA Form 483 risk; net impact neutral.
Commercial wins with Advanz (鈧�160 m milestones) and Dr. Reddy鈥檚 expand the oncology & autoimmune pipeline while Ivers-Lee adds downstream capacity. SEK 789 m of fresh equity plus a 50 bp interest cut strengthen liquidity and reduce cash burn. However, the Form 483 covers multiple quality-system gaps tied to four BLAs; approval timing for AVT02/03/05/06 now depends on FDA classification, creating binary regulatory risk. Overall, strategic momentum is positive but valuation upside is capped until inspection issues are fully resolved.
TL;DR 鈥� Form 483 elevates approval risk; remediation plan is submitted but outcome uncertain.
The inspection observations span manufacturing controls, documentation and lab practices鈥攁reas often requiring re-inspection. While management claims some issues are historical, FDA follow-up could delay launch-ready assets and trigger additional costs. Positive CHMP feedback on AVT06 underscores EU progress, yet U.S. revenue inflection depends on clearing the Form 483. Investors should monitor FDA鈥檚 classification letter (OAI, VAI or NAI) and potential impact on 2025鈥�26 launch schedules.
Il Form 6-K di Alvotech di luglio 2025 riporta le azioni di governance, commerciali, regolatorie e finanziarie intraprese dalla pubblicazione del rapporto del primo trimestre.
- Governance: Sei amministratori rieletti; la veterana Linda J贸nsd贸ttir nominata CFO; il COO Faysal Kalmoua lascia il consiglio e la direzione.
- Commerciale: Partnership con Advanz Pharma estesa a tre nuovi biosimilari (milestone fino a 160 milioni di euro) e accordo separato per AVT10 (Cimzia); co-sviluppo globale del biosimilare di Keytruda con Dr. Reddy鈥檚.
- M&A: Acquisizione del confezionatore svizzero Ivers-Lee e del team R&D svedese di Xbrane, oltre al candidato Cimzia per 275 milioni di corone svedesi.
- Pipeline: Opinione positiva CHMP per AVT06 (Eylea); studio su AVT23 (Xolair) dimostra equivalenza terapeutica.
- Rischio produttivo: Ispezione FDA pre-approvazione (26 giugno鈥�4 luglio) ha emesso il Form 483 evidenziando carenze operative, documentali e di controllo qualit脿; risposta dettagliata inviata il 25 luglio.
- Finanziamenti: IPO SDR sovrasottoscritta (39 milioni SEK) e collocamento istituzionale (750 milioni SEK) hanno aggiunto oltre 3.000 nuovi azionisti; modifica del prestito a termine che elimina la seconda tranche, riduce il margine a SOFR+6,0%, struttura ora a 1,081 miliardi di dollari, liquidit脿 di 152 milioni di dollari.
Il nuovo capitale e le partnership rafforzano le prospettive di crescita, ma la risoluzione delle questioni regolatorie 猫 fondamentale per le approvazioni BLA a breve termine.
El Formulario 6-K de Alvotech de julio de 2025 detalla las acciones de gobernanza, comerciales, regulatorias y financieras desde su informe del primer trimestre.
- Gobernanza: Seis directores reelegidos; la ejecutiva veterana Linda J贸nsd贸ttir nombrada CFO; el COO Faysal Kalmoua sale del consejo y la gesti贸n.
- Comercial: Ampliaci贸n de la colaboraci贸n con Advanz Pharma a tres nuevos biosimilares (hitos hasta 鈧�160 millones) y acuerdo separado para AVT10 (Cimzia); co-desarrollo global del biosimilar de Keytruda con Dr. Reddy鈥檚.
- Fusiones y Adquisiciones: Adquisici贸n del envasador suizo Ivers-Lee y del equipo de I+D sueco de Xbrane, adem谩s del candidato Cimzia por 275 millones de coronas suecas.
- Pipeline: Opini贸n positiva del CHMP para AVT06 (Eylea); estudio de AVT23 (Xolair) demuestra equivalencia terap茅utica.
- Riesgo de fabricaci贸n: Inspecci贸n pre-aprobaci贸n de la FDA (26 jun鈥�4 jul) emiti贸 el Formulario 483 se帽alando deficiencias operativas, documentales y de control de calidad; respuesta detallada enviada el 25 de julio.
- Financiamiento: IPO SDR sobresuscrita (39 millones SEK) y colocaci贸n institucional (750 millones SEK) suman m谩s de 3,000 nuevos accionistas; enmienda del pr茅stamo a plazo que elimina la segunda tranche, reduce el margen a SOFR+6.0%, facilidades ahora en $1.081 mil millones, efectivo $152 millones.
El nuevo capital y las alianzas mejoran las perspectivas de crecimiento, pero la remediaci贸n regulatoria es cr铆tica para las aprobaciones BLA a corto plazo.
Alvotech鞚� 2025雲� 7鞗� Form 6-K電� 1攵勱赴 氤搓碃靹� 鞚错泟鞚� 瓯半矂雱岇姢, 靸侅梾, 攴滌牅 氚� 鞛 頇滊彊鞚� 靸侅劯頌� 靹る獏頃╇媹雼�.
- 瓯半矂雱岇姢: 6氇呾潣 鞚挫偓 鞛劆鞛�; 氩犿厡霝� 鞛勳洂 Linda J贸nsd贸ttir臧� CFO搿� 鞛勲獏; COO Faysal Kalmoua電� 鞚挫偓須� 氚� 瓴届榿歆勳棎靹� 韲挫瀯.
- 靸侅梾: Advanz Pharma鞕�鞚� 韺岉姼雱堨嫮鞚� 3臧滌潣 鞁犼窚 氚旍澊鞓れ嫓氚�霟 頇曤寑(毵堨澕鞀ろ啢 斓滊寑 鈧�1鞏� 6觳滊); 氤勲弰 AVT10(Cimzia) 瓿勳暯 觳搓舶; Dr. Reddy鈥檚鞕� 鞝� 靹戈硠 Keytruda 氚旍澊鞓れ嫓氚�霟� 瓿惦彊 臧滊皽.
- M&A: 鞀れ渼鞀� 韽灔鞐呾泊 Ivers-Lee 氚� Xbrane鞚� 鞀れ洦雿� 鞐瓣惮臧滊皽韺�瓿� Cimzia 頉勲炒 氍检鞚� 齑� 2鞏� 7,500毵� SEK鞐� 鞚胳垬.
- 韺岇澊顶勲澕鞚�: AVT06(Eylea)鞐� 雽�頃� CHMP 旮嶌爼鞝� 鞚橁铂; AVT23(Xolair) 鞐瓣惮鞐愳劀 旃橂鞝� 霃欕摫靹� 鞛呾.
- 鞝滌“ 毽姢韥�: FDA 靷爠 鞀轨澑 瓴�靷�(6鞗� 26鞚紐7鞗� 4鞚�)鞐愳劀 鞖挫榿, 氍胳劀頇� 氚� 頀堨 甏�毽� 瓴绊暔鞚� 歆�鞝來晿電� Form 483 氚滍枆; 7鞗� 25鞚� 靸侅劯 雼惦硛 鞝滌稖.
- 鞛: 齑堦臣 觳暯霅� SDR IPO(3,900毵� SEK) 氚� 旮瓣磤 氚办爼(7鞏� 5,000毵� SEK)鞙茧 3,000氇� 鞚挫儊鞚� 鞁犼窚 欤检＜ 頇曤炒; 臁瓣贝攵� 雽�於� 靾橃爼鞙茧 霊� 氩堨Ц 韸鸽灉旃� 韽愳, 毵堨 SOFR+6.0%搿� 臁办爼, 鞁滌劋 頃滊弰電� 10鞏� 8,100毵� 雼煬, 順勱笀鞚� 1鞏� 5,200毵� 雼煬.
靸堧鞖� 鞛愲掣瓿� 韺岉姼雱堨嫮鞚� 靹膘灔 鞝勲鞚� 臧曧檾頃橃毵�, 雼赴 BLA 鞀轨澑鞐愲姅 攴滌牅 氍胳牅 頃搓舶鞚� 頃勳垬鞝侅瀰雼堧嫟.
Le Formulaire 6-K d'Alvotech de juillet 2025 d茅taille les actions de gouvernance, commerciales, r茅glementaires et financi猫res depuis son rapport du premier trimestre.
- Gouvernance : Six administrateurs r茅茅lus ; la cadre exp茅riment茅e Linda J贸nsd贸ttir nomm茅e CFO ; le COO Faysal Kalmoua quitte le conseil et la direction.
- Commercial : Partenariat avec Advanz Pharma 茅tendu 脿 trois nouveaux biosimilaires (jalons jusqu'脿 160 M鈧�) et accord s茅par茅 pour AVT10 (Cimzia) ; co-d茅veloppement mondial du biosimilaire de Keytruda avec Dr. Reddy鈥檚.
- Fusions & Acquisitions : Acquisition de l鈥檈mballeur suisse Ivers-Lee et de l鈥櫭﹒uipe R&D su茅doise de Xbrane, ainsi que du candidat Cimzia pour 275 MSEK.
- Pipeline : Avis positif du CHMP pour AVT06 (Eylea) ; 茅tude AVT23 (Xolair) d茅montrant une 茅quivalence th茅rapeutique.
- Risque de fabrication : Inspection pr茅-approbation FDA (26 juin鈥�4 juillet) ayant 茅mis un Form 483 signalant des d茅ficiences op茅rationnelles, documentaires et de contr么le qualit茅 ; r茅ponse d茅taill茅e soumise le 25 juillet.
- Financement : IPO SDR sursouscrite (39 MSEK) et placement institutionnel (750 MSEK) ajoutant plus de 3 000 nouveaux actionnaires ; modification du pr锚t 脿 terme supprimant la deuxi猫me tranche, r茅duisant la marge 脿 SOFR+6,0 %, facilit茅 port茅e 脿 1,081 Md$ et tr茅sorerie de 152 M$.
Les nouveaux capitaux et partenariats renforcent les perspectives de croissance, mais la correction r茅glementaire est cruciale pour les approbations BLA 脿 court terme.
Der Form 6-K von Alvotech im Juli 2025 beschreibt Governance-, kommerzielle, regulatorische und finanzielle Ma脽nahmen seit dem Q1-Bericht.
- Governance: Sechs Direktoren wiedergew盲hlt; erfahrene Managerin Linda J贸nsd贸ttir zur CFO ernannt; COO Faysal Kalmoua verl盲sst Vorstand und Management.
- Kommerziell: Partnerschaft mit Advanz Pharma auf drei neue Biosimilars ausgeweitet (Meilensteine bis zu 160 Mio. 鈧�) und separater AVT10 (Cimzia) Vertrag; globale Co-Entwicklung des Keytruda-Biosimilars mit Dr. Reddy鈥檚.
- M&A: Erwerb des Schweizer Verpackers Ivers-Lee sowie des schwedischen F&E-Teams von Xbrane plus Cimzia-Kandidaten f眉r 275 Mio. SEK.
- Pipeline: Positives CHMP-Gutachten f眉r AVT06 (Eylea); Studie zu AVT23 (Xolair) zeigt therapeutische 脛quivalenz.
- Herstellungsrisiko: FDA-Vorabinspektion (26. Juni鈥�4. Juli) stellte im Form 483 betriebliche, dokumentarische und Qualit盲tskontrollm盲ngel fest; detaillierte Antwort am 25. Juli eingereicht.
- Finanzierung: 脺berzeichnetes SDR-IPO (39 Mio. SEK) und institutionelle Platzierung (750 Mio. SEK) bringen >3.000 neue Aktion盲re; 脛nderung des Terminkredits hebt zweite Tranche auf, senkt Marge auf SOFR+6,0 %, Kreditrahmen nun 1,081 Mrd. USD, Cash 152 Mio. USD.
Neues Kapital und Partnerschaften st盲rken die Wachstumsaussichten, doch regulatorische Nachbesserungen sind f眉r kurzfristige BLA-Zulassungen entscheidend.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2025
SAFE BULKERS, INC.
(Translation of registrant’s name into English)
Apt. D11, Les Acanthes 6, Avenue des Citronniers, MC98000 Monaco
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained in the Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
INCORPORATION BY REFERENCE
This Report on Form 6-K shall be incorporated by reference into our registration statement on Form F-3, as filed with the Securities and Exchange Commission on August 6, 2024 and as may be further amended, to the extent not superseded by documents or reports subsequently filed by us under the Securities Act of 1933 or the Securities Exchange Act of 1934, in each case as amended.
EXHIBIT INDEX
1. Press Release dated July 28, 2025: Safe Bulkers, Inc. Announces Sale of a 2007-Built
Kamsarmax Class Dry-bulk Vessel.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 28, 2025
|
|
|
| SAFE BULKERS, INC. | |
| ||
| ||
| By: | /s/ Konstantinos Adamopoulos |
| Name: | Konstantinos Adamopoulos |
| Title: | Chief Financial Officer |
![[f72825sb6k001.jpg]](https://www.sec.gov/Archives/edgar/data/0001434754/000131786125000040/f72825sb6k001.jpg)
Safe Bulkers, Inc. Announces Sale of a 2007-Built
Kamsarmax Class Dry-bulk Vessel
Monaco – July 28, 2025 — Safe Bulkers, Inc. (the Company) (NYSE: SB), an international provider of marine drybulk transportation services, announced today that it has entered into an agreement for the sale of MV Pedhoulas Leader, a 2007 Japanese-built, Kamsarmax class, dry-bulk vessel, at a gross sale price of $12.5 million and forward delivery date between August and October 2025.
Dr. Loukas Barmparis, President of the Company commented: “As part of our fleet renewal strategy, we have sold one of our oldest vessels, having achieved the targeted sale price. Our Company has on order six modern energy-efficient vessels, four of which will be delivered to us within 2026.’’
About Safe Bulkers, Inc.
The Company is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along worldwide shipping routes for some of the world’s largest users of marine drybulk transportation services. The Company’s common stock, series C preferred stock and series D preferred stock are listed on the NYSE, and trade under the symbols “SB”, “SB.PR.C” and “SB.PR.D”, respectively.
Forward-Looking Statements
This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and in Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, the Company’s growth strategy and measures to implement such strategy, including expected vessel acquisitions and entering into further time charters. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, business disruptions due to natural disasters or other events, such as the COVID-19 pandemic, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, changes in the demand for dry-bulk vessels, competitive factors in the market in which the Company operates, changes in TCE rates, changes in fuel prices, risks associated with operations outside the United States, general domestic and international political conditions, tariffs imposed as a result of trade war and trade protectionism, uncertainty in the banking sector and other related market volatility, disruption of shipping routes due to political events, risks associated with vessel construction and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertakings to release any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information please contact:
Company Contact:
Dr. Loukas Barmparis
President
Safe Bulkers, Inc.
Tel.: +30 2 111 888 400
Fax: +30 2 111 878 500
E-Mail: [email protected]
Investor Relations / Media Contact:
Nicolas Bornozis, President Capital Link, Inc.
230 Park Avenue, Suite 1536 New York, N.Y. 10169
Tel.: (212) 661-7566
Fax: (212) 661-7526
E-Mail: [email protected]
Source:
FAQ
What regulatory setback did Alvotech (ALVO) disclose in the July 2025 6-K?
How much capital did Alvotech raise through recent share offerings?
What are the financial terms of the amended term-loan facility?
Which pipeline assets received positive European feedback?
What is the potential value of the expanded Advanz Pharma partnership?
